Free Trial
→ A free stock pick, from me to you (From Behind the Markets) (Ad)tc pixel
OTCMKTS:DSRLF

DiaSorin Earnings Date & Estimates

DiaSorin logo
$92.00 0.00 (0.00%)
As of 11/9/2026

DiaSorin is estimated to report earnings on Thursday, November 12, 2026.

Research:ProfileForecast

Upcoming Earnings Announcement

Announcement Date
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from DiaSorin

DiaSorin is expected to post earnings of $2.46 per share on revenue of $341.82 million.

Consensus Estimates

Consensus EPS
$2.46
Expected Revenue
$341.82 million

Prepare for the Earnings Call

DiaSorin Earnings FAQ

DiaSorin (OTCMKTS:DSRLF) is estimated to report earnings on Thursday, November 12, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect DiaSorin to post earnings of $2.46 per share for the quarter.

The consensus revenue estimate for DiaSorin is $341.82 million for the quarter.

DiaSorin Earnings Headlines

DiaSorin's Liaison Plex Gastrointestinal Flex test receives CE mark
November 9 at 7:54 AM  |  marketscreener.comM
DiaSorin S.p.A. (DSRLF) Q2 2026 Earnings Call Transcript
August 1, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4928960-diasorin-s-p-a-dsrlf-q2-2026-earnings-call-transcript
The Withdrawal You'll Never See on Your Statement
A proposal circulating in Washington, dubbed the Mar-a-Lago Accord, calls for tariffs and currency pressure to deliberately weaken the US dollar, making American exports cheaper. For savers, a weaker dollar can quietly reduce purchasing power even if account balances stay the same. Bishop Gold Group's free 2026 Gold IRA Guide explains how physical gold can be held inside a retirement account, including a common rollover mistake that can trigger a taxable distribution.tc pixel
November 10 at 1:00 AM  |  Bishop Gold Group (Ad)
DiaSorin speculated to have rebuffed takeover offer from US suitor - report
July 11, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/diasorin-speculated-to-have-rebuffed-takeover-offer-from-us-suitor-report/ar-AA27ES1G
DiaSorin S.p.A. (DSRLF) Q1 2026 Earnings Call Transcript
May 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4901628-diasorin-s-p-a-dsrlf-q1-2026-earnings-call-transcript
Diasorin S.p.A. (DSRLF)
April 19, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/dsrlf
See More DiaSorin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like DiaSorin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DiaSorin and other key companies, straight to your email.

About DiaSorin

DiaSorin (OTCMKTS:DSRLF) is an Italian diagnostics company that develops and markets in vitro diagnostic tests and instruments for clinical laboratories and hospitals. Its products support the detection and monitoring of a range of conditions, including infectious diseases, hormonal disorders, and autoimmune and metabolic conditions.

The company’s portfolio includes immunodiagnostic assays and molecular diagnostic tests, along with laboratory platforms such as its LIAISON systems. These products are designed to help laboratories conduct testing across multiple areas of clinical care.

DiaSorin traces its origins to the immunodiagnostics business of Sorin Biomedica and became an independent company in 2000. It serves customers internationally through subsidiaries and distribution partners, with a presence across Europe, the Americas, and other global markets.

View DiaSorin Profile
Earnings Tools